Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Sold by FORA Capital LLC

FORA Capital LLC cut its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 18.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 10,622 shares of the company’s stock after selling 2,352 shares during the quarter. FORA Capital LLC’s holdings in Vera Therapeutics were worth $469,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of VERA. Vanguard Group Inc. grew its holdings in Vera Therapeutics by 31.5% during the first quarter. Vanguard Group Inc. now owns 2,148,714 shares of the company’s stock worth $92,653,000 after acquiring an additional 515,106 shares during the period. Samlyn Capital LLC grew its stake in shares of Vera Therapeutics by 90.8% in the 2nd quarter. Samlyn Capital LLC now owns 1,231,911 shares of the company’s stock worth $44,571,000 after purchasing an additional 586,410 shares during the last quarter. First Light Asset Management LLC lifted its stake in Vera Therapeutics by 130.6% during the second quarter. First Light Asset Management LLC now owns 1,005,723 shares of the company’s stock valued at $36,387,000 after purchasing an additional 569,590 shares during the last quarter. Logos Global Management LP boosted its holdings in Vera Therapeutics by 65.2% during the second quarter. Logos Global Management LP now owns 950,000 shares of the company’s stock worth $34,371,000 after buying an additional 375,000 shares in the last quarter. Finally, Marshall Wace LLP grew its position in Vera Therapeutics by 9.2% in the second quarter. Marshall Wace LLP now owns 524,578 shares of the company’s stock worth $18,979,000 after buying an additional 44,059 shares during the last quarter. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Trading Up 2.9 %

Shares of NASDAQ:VERA opened at $48.83 on Friday. Vera Therapeutics, Inc. has a 12-month low of $12.58 and a 12-month high of $51.61. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. The firm has a fifty day moving average of $43.94 and a two-hundred day moving average of $39.65.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Thursday, November 7th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.21). Equities analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Wells Fargo & Company assumed coverage on Vera Therapeutics in a research report on Thursday, November 21st. They set an “overweight” rating and a $70.00 price objective for the company. Guggenheim increased their price target on Vera Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a research report on Monday, October 28th. JPMorgan Chase & Co. boosted their price objective on Vera Therapeutics from $72.00 to $75.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $107.00 target price on shares of Vera Therapeutics in a report on Tuesday, October 1st. Finally, Wedbush boosted their price target on shares of Vera Therapeutics from $30.00 to $38.00 and gave the company a “neutral” rating in a report on Friday, November 8th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $59.22.

Insiders Place Their Bets

In other news, Director Beth C. Seidenberg sold 15,000 shares of Vera Therapeutics stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $48.03, for a total value of $720,450.00. Following the transaction, the director now owns 131,553 shares of the company’s stock, valued at $6,318,490.59. This trade represents a 10.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Marshall Fordyce sold 15,625 shares of the business’s stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $37.50, for a total transaction of $585,937.50. Following the transaction, the chief executive officer now directly owns 307,972 shares of the company’s stock, valued at approximately $11,548,950. This represents a 4.83 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 89,927 shares of company stock valued at $3,800,796 over the last ninety days. Corporate insiders own 21.70% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.